Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian markets pare early gains
Thu, 19 Mar 01:30 pm

Federal Reserve comments catapulted Indian Markets with solid gains; however, the same got erased marginally in the post-noon session owing to profit booking. BSE Sensex is trading with a gain of 200 points while NSE-Nifty has advanced with gains of about 60 points. All the sectoral indices are trading in the green within which pharma stocks have gained the maximum, while IT stocks have gained the minimum. BSE Mid Cap and BSE Small Cap have traded with moderate gains of about 0.6% each.

Commodities, too, have gained on the back of Fed's comments on interest rates. Gold prices, per 10 grams, have gained over 1% or Rs 250 while silver prices, per kilogram, have increased over 1.8% or Rs 662. Crude oil prices which declined nearly 15% within one week have gained over 2%. Per barrel, crude oil prices have gained Rs 65. Indian currency has shown weakness since the Fed did not provide any clues of an immediate hike in interest rates. The value of Indian Rupee declined against the U.S Dollar by 0.44% or 0.28 and is currently trading near Rs 62.38 levels.

Most of the Asian stock markets closed today's trading session in the green. However, Japanese market suffered moderate losses of 0.4%. Chinese, Hong Kong, Taiwanese and Korean markets closed with 0.2%, 1.3%, 0.9% and 0.5% respective gains.

Shares of Religare securities gained nearly 1% after the company announced its futures plans of creating a portfolio of "social relevant assets" which fall under the REIT. Religare Global Asset Management, an arm of Religare securities, is planning to build a portfolio which would include assets that are socially relevant. It would predominantly include schools, hospitals, malls and cinemas. The company plans to raise nearly Rs 10 bn via this route within one year starting from June. On the back of real estate investments, Religare plans to raise nearly $500 mn.

Pharma stocks gained the maximum during today's trading session. Lupin lead the rally with more than 4% gains. Lupin's drug Celebrex received approval from ANDA following which shares of Lupin received investors' attention. Sun Pharma and Suven Life sciences, which are amongst today's lead gainers, have also received many drug approvals recently.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets pare early gains". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.